Different Effects of the ABCG2 C.421C>A SNP on the Pharmacokinetics of Fluvastatin, Pravastatin and Simvastatin
Abstract
AIMS: This study aimed to investigate possible effects of the ABCG2 c.421C>A (p.Gln141Lys; rs2231142) genotype on fluvastatin, pravastatin and simvastatin pharmacokinetics. MATERIALS & METHODS: In a crossover study, five healthy volunteers with the ABCG2 c.421A/A genotype, four with the c.421C/A genotype and 23 with the c.421C/C genotype ingested a single 40-mg dose of fluvastatin, pravastatin and simvastatin, with a washout period of 1 week. Plasma statin concentrations were measured up to 12 h. RESULTS: The estimated marginal mean area under the plasma concentration-time curve from 0 h to infinity (AUC(0-infinity)) of fluvastatin was 97% (p = 0.015) or 72% (p = 0.009) larger in participants with the A/A genotype than in those with the C/A or C/C genotype. The AUC(0-infinity) of simvastatin lactone was 111% (p = 0.005) larger in participants with the A/A genotype than in participants with the C/C genotype. The simvastatin acid:lactone AUC(0-infinity) ratio was 46% (p = 0.017) smaller in individuals with the A/A genotype than in those with the C/C genotype. The ABCG2 genotype had no significant effect on simvastatin acid or pravastatin pharmacokinetics. CONCLUSIONS: Genetic variability in ABCG2 markedly affects the pharmacokinetics of fluvastatin and simvastatin lactone, but has no significant effect on pravastatin or active simvastatin acid. Genotyping for ABCG2 in addition to SLCO1B1 and ABCB1 polymorphisms could help in predicting statin pharmacokinetics when selecting a statin and its dose for an individual patient.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The final PBPK models predicted the BCRP DGI ratios within twofold of the observed for poor or intermediate function.
“The final PBPK models predicted the DGI ratios within twofold of the observed for poor or intermediate function 29 , 36 .”
From Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction (2022) · cites this paper as [36]
There is limited availability of pharmacogenetic information, with only a few studies comprising a small number of subjects (4 to 15 individuals) for each transporter genotype.
“However, there is limited availability of pharmacogenetic information, with only a few studies comprising a small number of subjects (4 to 15 individuals) for each transporter genotype. 29 , 36”
From Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction (2022) · cites this paper as [36]
Although the presented models include BCRP-mediated cell membrane translocation, informed by the PK data reported by Keskitalo, these do not predict significant changes in AUC for the different BCRP genotypes.
“Although our presented models include BCRP‐mediated cell membrane translocation, informed by the PK data reported by Keskitalo, 36 these do not predict significant changes in AUC for the different BCRP genotypes (Figure S20 in Appendix S2).”
From Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction (2022) · cites this paper as [36]
Cites
<i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · see citing works
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463 · see citing works
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470 · see citing works
Self-citationPharmacogenetic Study of Statin Therapy and Cholesterol Reduction
Chasman, D. I. (2004) · JAMA · doi:10.1001/jama.291.23.2821 · Cited by 453 · see citing works
Imai, Y., Nakane, M., Kage, K., Tsukahara, S., Ishikawa, E., Tsuruo, T., Miki, Y., & Sugimoto, Y. (2002) · PubMed · Cited by 442 · see citing works
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 433 · see citing works
Self-citationABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
Keskitalo, J. E., Zolk, O., Fromm, M. F., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.79 · Cited by 417 · see citing works
Self-citationSLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409 · see citing works
Self-citationMizuarai, S., Aozasa, N., & Kotani, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11669 · Cited by 318 · see citing works
Zamber, C. P., Lamba, J. K., Yasuda, K., Farnum, J., Thummel, K. E., Schuetz, J. D., & Schuetz, E. G. (2003) · Pharmacogenetics · doi:10.1097/00008571-200301000-00004 · Cited by 272 · see citing works
FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA
Kobayashi, D., Ieiri, I., Hirota, T., Takane, H., Maegawa, S., Kigawa, J., Suzuki, H., Nanba, E., Oshimura, M., Terakawa, N., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001628 · Cited by 268 · see citing works
Functional Analysis of SNPs Variants of BCRP/ABCG2
Kondo, C., Suzuki, H., Itoda, M., Ozawa, S., Sawada, J.-I., Kobayashi, D., Ieiri, I., Mine, K., Ohtsubo, K., & Sugiyama, Y. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000045245.21637.d4 · Cited by 266 · see citing works
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males
Zhang, W., Yu, B., He, Y., Fan, L., Li, Q., Liu, Z., Wang, A., Liu, Y., Tan, Z., Jiang, F., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.05.010 · Cited by 263 · see citing works
Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin
Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., & Sugiyama, Y. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014019 · Cited by 256 · see citing works
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.010 · Cited by 250 · see citing works
Self-citationDiflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1
Sparreboom, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.003 · Cited by 241 · see citing works
Single nucleotide polymorphisms modify the transporter activity of ABCG2
Morisaki, K., Robey, R. W., Özvegy‐Laczka, C., Honjo, Y., Polgár, O., Steadman, K., Sarkadi, B., & Bates, S. E. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0931-x · Cited by 230 · see citing works
Neuvonen, P. J., Backman, J. T., & Niemi, M. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847070-00003 · Cited by 217 · see citing works
Self-citationFiegenbaum, M., DASILVEIRA, F., VANDERSAND, C., VANDERSAND, L., Ferreira, M. B. C., PIRES, R., & Hutz, M. H. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.003 · Cited by 216 · see citing works
van Herwaarden, A. E., & Schinkel, A. H. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.007 · Cited by 214 · see citing works
Ho, R. H., Choi, L., Lee, W., Mayo, G., Schwarz, U. I., Tirona, R. G., Bailey, D. G., Stein, C. M., & Kim, R. B. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3280ef698f · Cited by 198 · see citing works
Lipid-lowering response to statins is affected by CYP3A5 polymorphism
Kivistö, K. T., Niemi, M., Schaeffeler, E., Pitkälä, K. H., Tilvis, R. S., Fromm, M. F., Schwab, M. G., Eichelbaum, M. F., & Strandberg, T. E. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114762.78957.a5 · Cited by 193 · see citing works
Self-citationMatsushima, S., Maeda, K., Kondo, C., Hirano, M., Sasaki, M., Suzuki, H., & Sugiyama, Y. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085589 · Cited by 190 · see citing works
Yamasaki, Y., Ieiri, I., Kusuhara, H., Sasaki, T., Kimura, M., Tabuchi, H., Ando, Y., Irie, S., Ware, J., Nakai, Y., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100459 · Cited by 167 · see citing works
Effect of ABCG2 genotype on the oral vioavailability of topotecan
Sparreboom, A., Loos, W. J., Burger, H., Sissung, T. M., Verweij, J., Figg, W. D., Nooter, K., & Gelderblom, H. A. J. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.6.1731 · Cited by 163 · see citing works
Keskitalo, J. E., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.25 · Cited by 148 · see citing works
Self-citationUrquhart, B. L., Ware, J. A., Tirona, R. G., Ho, R. H., Leake, B. F., Schwarz, U. I., Zaher, H., Palandra, J., Gregor, J. C., Dresser, G. K., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f974dc · Cited by 141 · see citing works
Tamura, A., Wakabayashi, K., Onishi, Y., Takeda, M., Ikegami, Y., Sawada, S., Tsuji, M., Matsuda, Y., & Ishikawa, T. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00371.x · Cited by 129 · see citing works
Kajinami, K., Brousseau, M. E., Ordovás, J. M., & Schaefer, E. J. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.01.014 · Cited by 122 · see citing works
Functional interaction of intestinal CYP3A4 and P‐glycoprotein
Kivistö, K. T., Niemi, M., & Fromm, M. F. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00291.x · Cited by 121 · see citing works
Self-citationPasanen, M. K., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0123-1 · Cited by 119 · see citing works
Self-citationNiemi, M., Arnold, K. A., Backman, J. T., Pasanen, M. K., Gödtel‐Armbrust, U., Wojnowski, L., Zanger, U. M., Neuvonen, P. J., Eichelbaum, M. F., Kivistö, K. T., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230422.50962.91 · Cited by 109 · see citing works
Self-citationMulvana, D., Jemal, M., & Pulver, S. C. (2000) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(00)00372-1 · Cited by 62 · see citing works
DISPOSITION OF ORAL AND INTRAVENOUS PRAVASTATIN IN MRP2-DEFICIENT TR– RATS
Kivistö, K. T., Grisk, O., Hofmann, U., Meissner, K., Möritz, K.-U., Ritter, C. A., Arnold, K. A., Lutjöohann, D., von Bergmann, K., Klöting, I., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006262 · Cited by 58 · see citing works
Schoeller, D. A., Colligan, A. S., Shriver, T. C., Avak, H., & Bartok, C. (2000) · Journal of Mass Spectrometry · doi:10.1002/1096-9888(200009)35:9 · Cited by 54 · see citing works
Apostolou, C. D., Kousoulos, C., Dotsikas, Y., Soumelas, G.-S., Kolocouri, F., Ziaka, A., & Loukas, Y. L. (2007) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2007.12.001 · Cited by 42 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 676 · see citing works
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 636 · see citing works
Self-citationTransporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 576 · see citing works
Drug Transporters in Drug Efficacy and Toxicity
DeGorter, M. K., Xia, C. Q., Yang, J. J., & Kim, R. B. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134529 · Cited by 359 · see citing works
Transporter Pharmacogenetics and Statin Toxicity
Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.197 · Cited by 329 · see citing works
Self-citationDrug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective
Prueksaritanont, T., Chu, X., Gibson, C. R., Cui, D., Yee, K. L., Ballard, J. E., Cabalu, T. D., & Hochman, J. H. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9470-x · Cited by 249 · see citing works
Renal Drug Transporters and Drug Interactions
Ivanyuk, A., Livio, F., Biollaz, J., & Buclin, T. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0506-8 · Cited by 221 · see citing works
What is a relevant statin concentration in cell experiments claiming pleiotropic effects?
Björkhem‐Bergman, L., Lindh, J. D., & Bergman, P. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03907.x · Cited by 207 · see citing works
Elsby, R., Hilgendorf, C., & Fenner, K. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.163 · Cited by 198 · see citing works
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
Hirota, T., Fujita, Y., & Ieiri, I. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1801634 · Cited by 190 · see citing works
Ieiri, I. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rv-098 · Cited by 164 · see citing works
Myotoxicity of statins: Mechanism of action
du Souich, P., Roederer, G. O., & Dufour, R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.029 · Cited by 162 · see citing works
Bruhn, O., & Cascorbi, I. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.952630 · Cited by 157 · see citing works
Chauvin, B., Drouot, S., Barrail‐Tran, A., & Taburet, A. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0075-4 · Cited by 154 · see citing works
Lee, C. A., O'Connor, M., Ritchie, T. K., Galetin, A., Cook, J., Ragueneau, I., Ellens, H. M., Feng, B., Taub, M. E., Paine, M. F., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062174 · Cited by 142 · see citing works
Targeting Intestinal Transporters for Optimizing Oral Drug Absorption
Varma, M. V. S., Ambler, C. M., Ullah, M., Rotter, C. J., Sun, H., Litchfield, J., Fenner, K. S., & El‐Kattan, A. F. (2010) · Current Drug Metabolism · doi:10.2174/138920010794328850 · Cited by 127 · see citing works
Prasad, B., Lai, Y., Lin, Y. S., & Unadkat, J. D. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23436 · Cited by 115 · see citing works
Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites
Patel, M., Taskar, K. S., & Zamek‐Gliszczynski, M. J. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.671 · Cited by 114 · see citing works
Oral Absorption, Intestinal Metabolism and Human Oral Bioavailability
El‐Kattan, A. F., & Varm, M. (2012) · InTech eBooks · doi:10.5772/31087 · Cited by 104 · see citing works
Use of Transporter Knockdown Caco-2 Cells to Investigate the In Vitro Efflux of Statin Drugs
Li, J., Volpe, D. A., Wang, Y., Zhang, W., Bode, C., Owen, A. J., & Hidalgo, I. J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038075 · Cited by 97 · see citing works
Hira, D., & Terada, T. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.10.004 · Cited by 91 · see citing works
zu Schwabedissen, H. E. M., & Kroemer, H. K. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-14541-4_9 · Cited by 89 · see citing works
Heyes, N., Kapoor, P., & Kerr, I. D. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083030 · Cited by 86 · see citing works
Bruckmueller, H., & Cascorbi, I. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1876661 · Cited by 77 · see citing works
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review
Canestaro, W. J., Austin, M. A., & Thummel, K. E. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.41 · Cited by 81 · see citing works
Interaction of Drug or Food with Drug Transporters in Intestine and Liver
Nakanishi, T., & Tamai, I. (2015) · Current Drug Metabolism · doi:10.2174/138920021609151201113537 · Cited by 76 · see citing works
Molecular mechanisms of statin intolerance
Gluba-Brzózka, A., Franczyk, B., Toth, P. P., Rysz, J., & Banach, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.59938 · Cited by 73 · see citing works
Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers
Allred, A. J., Bowen, C. J., Park, J. W., Peng, B., Williams, D. D., Wire, M. B., & Lee, E. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03972.x · Cited by 72 · see citing works
Tsamandouras, N., Dickinson, G., Guo, Y., Hall, S., Rostami-Hodjegan, A., Galetin, A., & Aarons, L. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.55 · Cited by 68 · see citing works
Kim, H. R., Park, H. S., Kwon, W. S., Lee, J. H., Tanigawara, Y., Lim, S. M., Kim, H. S., Shin, S. J., Ahn, J. B., & Rha, S. Y. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2258-y · Cited by 67 · see citing works
Ferrari, M., Guasti, L., Maresca, A. M., Mirabile, M., Contini, S., Grandi, A. M., Marino, F., & Cosentino, M. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1661-6 · Cited by 66 · see citing works
Feng, Q., Wilke, R. A., & Baye, T. M. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.11 · Cited by 64 · see citing works
Comparative Hepatic and Intestinal Efflux Transport of Statins
Deng, F. Y., Tuomi, S.-K., Neuvonen, M., Hirvensalo, P., Kulju, S., Wenzel, C., Oswald, S., Filppula, A. M., & Niemi, M. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000430 · Cited by 65 · see citing works
Self-citationLemos, C., Giovannetti, E., Zucali, P. A., Assaraf, Y. G., Scheffer, G. L., van der Straaten, T., D’Incecco, A., Falcone, A., Guchelaar, H., Danesi, R., et al. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.172 · Cited by 65 · see citing works
Lai, Y., Varma, M. V. S., Feng, B., Stephens, J. C., Kimoto, E., El‐Kattan, A. F., Ichikawa, K., Kikkawa, H., Ono, C., Suzuki, A., et al. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.678048 · Cited by 61 · see citing works
Generaux, G. T., Bonomo, F., Johnson, M., & Doan, K. M. M. (2011) · Xenobiotica · doi:10.3109/00498254.2011.562566 · Cited by 61 · see citing works
Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Liu, J. J., Lu, J., & McKeage, M. J. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912803251199 · Cited by 60 · see citing works
Hu, M., To, K. K. W., Mak, V. W. L., & Tomlinson, B. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.538383 · Cited by 58 · see citing works
Pharmacogenomics of Membrane Transporters: Past, Present and Future
Yee, S. W., Chen, L., & Giacomini, K. M. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.22 · Cited by 52 · see citing works
Terada, T., & Hira, D. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1061-4 · Cited by 50 · see citing works
Choi, H. Y., Bae, K.-S., Cho, S.-H., Ghim, J.-L., Choe, S., Jung, J. A., Jin, S.-J., Kim, H.-S., & Lim, H.-S. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000176 · Cited by 49 · see citing works
Polli, J. W., Hussey, E. K., Bush, M., Generaux, G. T., Smith, G. A., Collins, D., McMullen, S. L., Turner, N., & Nunez, D. J. (2012) · Xenobiotica · doi:10.3109/00498254.2012.739719 · Cited by 48 · see citing works
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins
Arrigoni, E., Re, M. D., Fidilio, L., Fogli, S., Danesi, R., & Paolo, A. D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010104 · Cited by 52 · see citing works
Poirier, A., Portmann, R., Cascais, A., Bader, U., Walter, I., Ullah, M., & Funk, C. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058248 · Cited by 46 · see citing works
Martin, P. D., Gillen, M. S., Ritter, J. M., Mathews, D. R., BREALEY, C. J., Surry, D. D., Oliver, S. D., Holmes, V., Severin, P., & Elsby, R. (2016) · Drugs in R&D · doi:10.1007/s40268-015-0120-x · Cited by 46 · see citing works
Genomewide Association Study of Simvastatin Pharmacokinetics
Mykkänen, A. J. H., Taskinen, S., Neuvonen, M., Paile‐Hyvärinen, M., Tarkiainen, E. K., Lilius, T. O., Tapaninen, T., Backman, J. T., Tornio, A., & Niemi, M. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2674 · Cited by 46 · see citing works
Self-citationABCG2 Gene Polymorphisms as Risk Factors for Atorvastatin Adverse Reactions: A Case–Control Study
Skvrce, N. M., Šarinić, V. M., Šimić, I., Ganoci, L., Katanec, D. M., & Božina, N. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.47 · Cited by 40 · see citing works
Umehara, K., Cantrill, C., Wittwer, M., Lenarda, E. D., Klammers, F., Ekiciler, A., Parrott, N. J., Fowler, S. M., & Ullah, M. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000133 · Cited by 40 · see citing works
Genetic and immunologic susceptibility to statin-related myopathy
Patel, J., Superko, H. R., Martin, S. S., Blumenthal, R. S., & Christopher‐Stine, L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.025 · Cited by 38 · see citing works
Wojtyniak, J., Selzer, D., Schwab, M., & Lehr, T. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2111 · Cited by 38 · see citing works
Hu, M., & Tomlinson, B. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.851667 · Cited by 37 · see citing works
An update on efflux and uptake transporters as determinants of statin response
Rocha, K. C. E., Pereira, B. M. V., & Rodrigues, A. C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1482276 · Cited by 37 · see citing works
Varma, M. V. S., & El‐Kattan, A. F. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.695 · Cited by 36 · see citing works
Lehtisalo, M., Keskitalo, J. E., Tornio, A., Lapatto‐Reiniluoto, O., Deng, F. Y., Jaatinen, T., Viinamäki, J., Neuvonen, M., Backman, J. T., & Niemi, M. (2020) · Clinical and Translational Science · doi:10.1111/cts.12809 · Cited by 36 · see citing works
Self-citationComparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins
Filppula, A. M., Hirvensalo, P., Parviainen, H., Ivaska, V. E., Lönnberg, K. I., Deng, F. Y., Viinamäki, J., Kurkela, M. J., Neuvonen, M., & Niemi, M. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000406 · Cited by 36 · see citing works
Self-citationFohner, A. E., Brackman, D. J., Giacomini, K. M., Altman, R. B., & Klein, T. E. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000305 · Cited by 36 · see citing works
Kitzmiller, J. P. (2014) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000128 · Cited by 35 · see citing works
Enantiospecific Pharmacogenomics of Fluvastatin
Hirvensalo, P., Tornio, A., Neuvonen, M., Kiander, W., Kidron, H., Paile‐Hyvärinen, M., Tapaninen, T., Backman, J. T., & Niemi, M. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1463 · Cited by 35 · see citing works
Self-citationSkvrce, N. M., Božina, N., Zibar, L., Barišić, I., Ganoci, L., & Šarinić, V. M. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.135 · Cited by 35 · see citing works
Effectiveness of high dose dexamethasone in the treatment of acute stroke.
Ogun, S. A., & Odusote, K. A. (2001) · PubMed · Cited by 35 · see citing works
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
Mueller, J., Schimmer, R. R., Koch, C., Schneiter, F., Fullin, J., Lysenko, V., Pellegrino, C. E., Klemm, N., Russkamp, N. F., Myburgh, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00024-2 · Cited by 33 · see citing works
Interaction of Food Additives with Intestinal Efflux Transporters
Sjöstedt, N., Deng, F. Y., Rauvala, O., Tepponen, T., & Kidron, H. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00563 · Cited by 34 · see citing works
Interaction potential between clarithromycin and individual statins—A systematic review
Christensen, M. M. H., Haastrup, M. B., Øhlenschlæger, T., Esbech, P. S., Pedersen, S. A., Dunvald, A. D., Stage, T. B., Henriksen, D. P., & Pedersen, A. J. T. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13343 · Cited by 34 · see citing works
Medically Important Alterations in Transport Function and Trafficking of ABCG2
Homolya, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062786 · Cited by 34 · see citing works
Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes
Xu, D., Li, F., Zhang, M., Zhang, J., Liu, C., Hu, M., Zhong, Z., Jia, L.-L., Wang, D., Wu, J., et al. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.39 · Cited by 33 · see citing works
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Chan, T., Chin, Y. M., & Low, S. (2019) · Oncology and Therapy · doi:10.1007/s40487-018-0090-6 · Cited by 35 · see citing works
Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia
Maxwell, W. D., Ramsey, L. B., Johnson, S. G., Moore, K. G., Shtutman, M. S., Schoonover, J. H., & Kawaguchi‐Suzuki, M. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1981 · Cited by 32 · see citing works
Cellular Processing of the ABCG2 Transporter—Potential Effects on Gout and Drug Metabolism
Mózner, O., Bartos, Z., Zámbó, B., Homolya, L., Hegedűs, T., & Sarkadi, B. (2019) · Cells · doi:10.3390/cells8101215 · Cited by 32 · see citing works
Mellal, A. A., Hussain, N., & Said, A. S. A. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s214938 · Cited by 32 · see citing works
Schnepf, R., & Zolk, O. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.742063 · Cited by 30 · see citing works
Piechota-Polańczyk, A., Kopacz, A., Klóska, D., Zagrapan, B., Neumayer, C., Grochot‐Przeczek, A., Huk, I., Brostjan, C., Dulak, J., & Józkowicz, A. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2028936 · Cited by 30 · see citing works
Domjanović, I. K., Lovrić, M., Trkulja, V., Petelin‐Gadže, Ž., Ganoci, L., Čajić, I., & Božina, N. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13646 · Cited by 30 · see citing works
When the same treatment has different response: The role of pharmacogenomics in statin therapy
Zheng, E., Madura, P., Grandos, J., Broncel, M., Pawlos, A., Woźniak, E., & Gorzelak‐Pabiś, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115966 · Cited by 27 · see citing works
Karibe, T., Hagihara-Nakagomi, R., Abe, K., Imaoka, T., Mikkaichi, T., Yasuda, S., Hirouchi, M., Watanabe, N., Okudaira, N., & Izumi, T. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1563-4 · Cited by 27 · see citing works
Drug transport by breast cancer resistance protein
Poguntke, M., Hazai, E., Fromm, M. F., & Zolk, O. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.519700 · Cited by 27 · see citing works
Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients
Szabó, E., Kulin, A., Koranyi, L. I., Literáti-Nagy, B., Cserepes, J., Somogyi, A., Sarkadi, B., & Várady, G. (2021) · Scientific Reports · doi:10.1038/s41598-021-82417-8 · Cited by 26 · see citing works
Pharmacogenomics and adverse drug reactions: the case of statins
Giorgi, M. A., Caroli, C., Arazi, H. C., & Girolamo, G. D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.563734 · Cited by 26 · see citing works
Racial Disparity in Drug Disposition in the Digestive Tract
Gao, S., Bell, E. C., Zhang, Y., & Liang, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031038 · Cited by 25 · see citing works
Karibe, T., Imaoka, T., Abe, K., & Ando, O. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078931 · Cited by 25 · see citing works
Pharmacogenomics of Lipid-Lowering Therapies
Hu, M., & Tomlinson, B. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.71 · Cited by 24 · see citing works
Itkonen, M. K., Tornio, A., Neuvonen, M., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065938 · Cited by 24 · see citing works
Self-citationIs personalized medicine a dream or a reality?
Morse, B. L., & Kim, R. B. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.950407 · Cited by 23 · see citing works
Otero, J. A., Real, R., de la Fuente, Á., Prieto, J. G., Marqués, M. M., Álvarez, A. I., & Merino, G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.049056 · Cited by 23 · see citing works
Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants
Lönnberg, K. I., Tornio, A., Hirvensalo, P., Keskitalo, J. E., Mustaniemi, A.-L., Kiiski, J. I., Filppula, A. M., & Niemi, M. (2023) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000504 · Cited by 22 · see citing works
Self-citationTanaka, Y., Kitamura, Y., Maeda, K., & Sugiyama, Y. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24366 · Cited by 22 · see citing works
Simvastatin improves mitochondrial respiration in peripheral blood cells
Durhuus, J. A., Hansson, S., Morville, T. H., Kuhlman, A. B., Dohlmann, T. L., Larsen, S., Helge, J. W., Angleys, M., Muniesa-Vargas, A., Bundgaard, J. R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73896-2 · Cited by 21 · see citing works
Prieto Garcia, L., Lundahl, A., Ahlström, C., Vildhede, A., Lennernäs, H., & Sjögren, E. (2022) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12837 · Cited by 21 · see citing works
Schwarz, T., Montanari, F., Cseke, A., Wlcek, K., Visvader, L., Palme, S., Chiba, P., Kuchler, K., Urban, E., & Ecker, G. F. (2016) · ChemMedChem · doi:10.1002/cmdc.201500592 · Cited by 20 · see citing works
Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin
Lehtisalo, M., Tarkiainen, E. K., Neuvonen, M., Holmberg, M. T., Kiiski, J. I., Lapatto‐Reiniluoto, O., Filppula, A. M., Kurkela, M. J., Backman, J. T., & Niemi, M. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3067 · Cited by 19 · see citing works
Self-citationThe ABCG2 Multidrug Transporter
Basseville, A., Hall, M. D., Chau, C. H., Robey, R. W., Gottesman, M. M., Figg, W. D., & Bates, S. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-23476-2_9 · Cited by 19 · see citing works
Lehtisalo, M., Kiander, W., Filppula, A. M., Deng, F. Y., Kidron, H., Korhonen, M. K., Sinkko, J., Koivula, K., & Niemi, M. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15684 · Cited by 18 · see citing works
Self-citationTo, K. K. W., Hu, M., & Tomlinson, B. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.58 · Cited by 18 · see citing works
Wegler, C., Gazit, M., Issa, K., Subramaniam, S., Artursson, P., & Karlgren, M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.09.039 · Cited by 18 · see citing works
Fišar, Z., Hroudová, J., Singh, N., Kopřivová, A., & Maceckova, D. (2016) · Folia Biologica · doi:10.14712/fb2016062020053 · Cited by 18 · see citing works
Allegra, S., Francia, S. D., Cusato, J., Arduino, A., Massano, D., Longo, F., Piga, A. G., & D’Avolio, A. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0176 · Cited by 18 · see citing works
Pediatric Statin Administration: Navigating a Frontier with Limited Data
Wagner, J. B., & Abdel‐Rahman, S. M. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.5.380 · Cited by 17 · see citing works
Hashimoto, Y., Michiba, K., Maeda, K., & Kusuhara, H. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.10.010 · Cited by 17 · see citing works
Futatsugi, A., Toshimoto, K., Yoshikado, T., Sugiyama, Y., & Kato, Y. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078816 · Cited by 16 · see citing works
Knežević, S., Filippi-Arriaga, F., Belančić, A., Božina, T., Mršić‐Pelčić, J., & Vitezić, D. (2024) · Diabetology · doi:10.3390/diabetology5040031 · Cited by 15 · see citing works
Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?
McLean, C., Wilson, A. S., & Kim, R. B. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.691 · Cited by 15 · see citing works
- Authors
- Keskitalo, J. E., Pasanen, M. K., Neuvonen, P. J., & Niemi, M.
- Affiliations
- Helsinki University Hospital (FI)
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2009-10
- Volume
- 10
- Issue
- 10
- Pages
- 1617-1624
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W1985219174
- Cited by
- 189
- References
- 37
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 11 · 2023: 7 · 2022: 10 · 2021: 18 · 2020: 7 · 2019: 7 · 2018: 11 · 2017: 16 · 2016: 13 · 2015: 10 · 2014: 17 · 2013: 20 · 2012: 14
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sigrid Jusélius Foundation
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- ABCG2, rs2231142, fluvastatin, pravastatin, simvastatin, statin pharmacokinetics, genetic variation, drug metabolism, SLCO1B1, P-glycoprotein, statin selection
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Fluvastatin, Adult, Fatty Acids, Monounsaturated, Female, Genotype, Half-Life, Humans, Indoles, Male, Metabolic Clearance Rate, Neoplasm Proteins, Genetic Variation, Pravastatin, ATP-Binding Cassette Transporters, Cross-Over Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Area Under Curve, Simvastatin, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
